Authors:
Prakash, S
Walele, A
Dimkovic, N
Bargman, J
Vas, S
Oreopoulos, D
Citation: S. Prakash et al., Experience with a large dose (500 mg) of intravenous iron dextran and ironsaccharate in peritoneal dialysis patients, PERIT DIA I, 21(3), 2001, pp. 290-295
Citation: S. Vas, On the recent recommendations of the ad hoc advisory committee on peritonitis management - Or should ceftazidime be used as initial empiric therapy? Dr. Vas Replies, PERIT DIA I, 21(3), 2001, pp. 320-321
Authors:
Keane, WF
Bailie, GR
Boeschoten, E
Gokal, R
Golper, TA
Holmes, CJ
Kawaguchi, Y
Piraino, B
Riella, M
Vas, S
Citation: Wf. Keane et al., Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update, PERIT DIA I, 20(4), 2000, pp. 396-411
Authors:
Billa, V
Zhong, AM
Bargman, J
Vas, S
Wong, PY
Oreopoulos, DG
Citation: V. Billa et al., High prevalence of hyperparathyroidism among peritoneal dialysis patients:A review of 176 patients, PERIT DIA I, 20(3), 2000, pp. 315-321
Authors:
Gabella, P
Singhal, M
Szabo, T
Vas, S
Oreopoulos, DG
Citation: P. Gabella et al., Therapy with gastric acid inhibitors is not related to enteric peritonitisin peritoneal dialysis, PERIT DIA I, 18(6), 1998, pp. 656-657